Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14614834 | 0.90 | FGFR1 (0.42) | BRAFCSF1RCYP2C9MAPK14JAK2 | |
| SCHEMBL927380 | 0.86 | FGFR1 (0.53) | PDGFRBFGFR1 | |
| SCHEMBL5042298 | 0.85 | CSF1R (0.54) | BRAFCSF1RCYP2C9MAPK14JAK2 | |
| SCHEMBL5033066 | 0.84 | KCNQ3 (0.44) | BRAFCSF1RCYP2C9MAPK14JAK2 | |
| SCHEMBL5033059 | 0.83 | SYK (0.51) | BRAFCSF1RMAPK14JAK2PDGFRB | |
| SCHEMBL928609 | 0.81 | PTGS1 (0.51) | BRAFCSF1RCYP2C9MAPK14JAK2 | |
| SCHEMBL12908049 | 0.79 | CSF1R (0.47) | BRAFCSF1RCYP2C9MAPK14JAK2 | |
| SCHEMBL928109 | 0.79 | FGFR1 (0.68) | PDGFRBFGFR1 | |
| SCHEMBL12908056 | 0.76 | FGFR1 (0.55) | PDGFRBFGFR1 | |
| SCHEMBL927776 | 0.74 | FGFR1 (0.53) | PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| EP-2099797-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-09-29 | — | — | EP | disclosed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| EP-1673343-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| EP-1673343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-28 | — | — | EP | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SGK2, BRSK2, FYN | BRAF 73/4885CSF1R 766/4885CYP2C9 4761/4885 |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | BRAF 45/4885CSF1R 692/4885CYP2C9 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.